Latest News - AMD

Monday, February 06, 2017 | Acquisitions/Mergers, AMD

BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Retinal Disease Therapy From University of Pittsburgh Medical Center

BioTime announced the acquisition of global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh’s Medical Center (UPMC), via the school’s Innovat…

Read the full story

Friday, February 03, 2017 | Medical Studies, Retina, AMD

Dexamethasone Implant With Anti-VEGF Explored for Wet AMD

Used in combination with antivascular endothelial growth factor (anti-VEGF) therapy, dexamethasone implants (0.7 mg Ozurdex, Allergan) may help some patients with neovascular age-related macular degen…

Read the full story

Thursday, February 02, 2017 | Clinical Trials, AMD, Genentech

Genentech Completes Patient Enrollment in Two Large Phase 3 Studies for Lampalizumab

Genentech has completed enrollment in two large phase 3 clinical trials, Chroma and Spectri, investigating the efficacy and safety of lampalizumab in reducing the progression of geographic atrophy (GA…

Read the full story

Wednesday, February 01, 2017 | Management/Leadership, AMD, Ophthotech

Ophthotech Announces Strategic Review Plan

Ophthotech announced that it has initiated a plan to review its strategic alternatives in order to maximize shareholder value. Without limiting any option, the principal focus of this plan is to activ…

Read the full story

Monday, January 30, 2017 | Product Releases, AMD, Genentech

Lucentis 0.5 mg Prefilled Syringe Now Available to Order in the US

Ophthalmologists across the United States can now order the Lucentis 0.5 mg prefilled syringe (PFS). The PFS is a new method of administering Lucentis to treat people with wet age-related macular dege…

Read the full story

Friday, January 13, 2017 | Acquisitions/Mergers, AMD, ForSight Vision

ForSight Vision 4 Announces Acquisition by Roche

ForSight Vision 4 announced that it has been acquired by Roche Holdings. The acquisition expands Roche's exclusive access to the ForSight Vision 4 PDS technology for long-acting delivery of therap…

Read the full story

Thursday, January 12, 2017 | Clinical Trials, AMD

FDA Grants "Safe to Proceed" Status to Hemera Biosciences' Gene Therapy IND Application

Hemera Biosciences has announced that the FDA has granted “safe to proceed” status to the investigational new drug application for HMR59 on December 30, 2016. A phase 1 clinical trial in p…

Read the full story

Friday, January 06, 2017 | Partnerships, AMD

Lin Bioscience Licenses First-in-Class Therapeutic Program to Treat Dry AMD from Columbia University in Collaboration with NIH

Lin Bioscience and Columbia Technology Ventures announced that Lin Bioscience has licensed the intellectual property portfolio and development program for a first-in-class medication intended to slow …

Read the full story

Friday, January 06, 2017 | FDA Approval/Clearance, Acucela, AMD

Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease

Acucela announced that the FDA granted orphan drug designation to Acucela’s leading drug candidate emixustat hydrochloride for the treatment of Stargardt disease. The orphan drug designation doe…

Read the full story

Wednesday, December 14, 2016 | Acquisitions/Mergers, Acucela, AMD

Acucela Secures Option to Exclusively Acquire Novel Retinal Technology

Acucela announced an R&D agreement and exclusive option to acquire the global rights to EyeMedics' proprietary biomimetic technology, including an initial candidate molecule for ophthalmic use…

Read the full story